Evidence map›Paper›PMID 26715471›Full record

ArticleJournal of translational medicine2015

Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats.

Andreia G F Friques, Clarisse M Arpini, Ieda C Kalil, Agata L Gava, Marcos A Leal, Marcella L Porto, Breno V Nogueira, Ananda T Dias, Tadeu U Andrade, Thiago Melo C Pereira and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03649828 (USE OF KEFIR AS A CO-ADJUVANT IN THE TREATMENT OF METABOLIC SYNDROME COMPONENTS), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03649828 nacompletednot on this mapstarted 2016, after this paper: background citation

USE OF KEFIR AS A CO-ADJUVANT IN THE TREATMENT OF METABOLIC SYNDROME COMPONENTS: a Double-blind, Randomized, Placebo Controlled Clinical Trial

TypeinterventionalSponsorUniversity Vila VelhaRan2016 to 2017Enrolled48ConditionsMetabolic Syndrome, Cardiovascular Diseases, HypertensionArmsprobiotic milk fermented with kefir grains, curd
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Journal of microbiology and biotechnology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Potential effects of probiotics on atherosclerosis.Microbiome research reports · 2025
    Review
  11. Review
  12. International journal of molecular sciences · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Gut microbiota: a potential new regulator of hypertension.Frontiers in cardiovascular medicine · 2024
    Review
  17. Article
  18. Probiotics: functional food ingredients with the potential to reduce hypertension.Frontiers in cellular and infection microbiology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Andreia G F FriquesPharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. andreiafriques@hotmail.com.
Clarisse M ArpiniPharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. clarisse.arpini@uvv.br.
Ieda C KalilPharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. ieda@uvv.br.
Agata L GavaDivision of Nephrology, McMaster University, Hamilton, ON, Canada. agatagava@hotmail.com.
Marcos A LealLaboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, ES, Brazil. marcos.emescam@gmail.com.
Marcella L PortoLaboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, ES, Brazil. cella.porto@gmail.com.
Breno V NogueiraDepartment of Morphology, Federal University of Espirito Santo, Vitoria, ES, Brazil. brenovalentim@gmail.com.
Ananda T DiasLaboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, ES, Brazil. anandatd@yahoo.com.br.
Tadeu U AndradePharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. tadeu.uggere@uvv.br.
Thiago Melo C PereiraPharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. pereiratmc@gmail.com.
Silvana S MeyrellesLaboratory of Translational Physiology, Federal University of Espirito Santo, Vitoria, ES, Brazil. meyrelle.vix@terra.com.br.
Bianca P CampagnaroPharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. biancacampagnaro@yahoo.com.br.
Elisardo C VasquezPharmaceutical Sciences Graduate Program, Vila Velha University, Vila Velha, ES, Brazil. evasquez@terra.com.br.
Universidade Federal do Espírito Santo · BRUniversidade Vila Velha · BRMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe beverage obtained by fermentation of milk with kefir grains, a complex matrix containing acid bacteria and yeasts, has been shown to have beneficial effects in various diseases. However, its effects on hypertension and endothelial dysfunction are not yet clear. In this study, we evaluated the effects of kefir on endothelial cells and vascular responsiveness in spontaneously hypertensive rats (SHR).

methodsSHR were treated with kefir (0.3 mL/100 g body weight) for 7, 15, 30 and 60 days and compared with non-treated SHR and with normotensive Wistar-Kyoto rats. Vascular endothelial function was evaluated in aortic rings through the relaxation response to acetylcholine (ACh). The balance between reactive oxygen species (ROS) and nitric oxide (NO) synthase was evaluated through specific blockers in the ACh-induced responses and through flow cytometry in vascular tissue.

resultsSignificant effects of kefir were observed only after treatment for 60 days. The high blood pressure and tachycardia exhibited by the SHR were attenuated by approximately 15 % in the SHR-kefir group. The impaired ACh-induced relaxation of the aortic rings observed in the SHR (37 ± 4 %, compared to the Wistar rats: 74 ± 5 %), was significantly attenuated in the SHR group chronically treated with kefir (52 ± 4 %). The difference in the area under the curve between before and after the NADPH oxidase blockade or NO synthase blockade of aortic rings from SHR were of approximately +90 and -60 %, respectively, when compared with Wistar rats. In the aortic rings from the SHR-kefir group, these values were reduced to +50 and -40 %, respectively. Flow cytometric analysis of aortic endothelial cells revealed increased ROS production and decreased NO bioavailability in the SHR, which were significantly attenuated by the treatment with kefir. Scanning electronic microscopy showed vascular endothelial surface injury in SHR, which was partially protected following administration of kefir for 60 days. In addition, the recruitment of endothelial progenitor cells was decreased in the non-treated SHR and partially restored by kefir treatment.

conclusionsKefir treatment for 60 days was able to improve the endothelial function in SHR by partially restoring the ROS/NO imbalance and the endothelial architecture due to endothelial progenitor cells recruitment.

Indexed as

Cultured Milk ProductsProbioticsAnimalsEndothelium, VascularFlow CytometryHypertensionMicroscopy, Electron, ScanningRatsRats, Inbred SHR

Identifiers

PMID26715471
PMCPMC4696190
OpenAlexW2221294414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.